Niramai

Niramai is a pioneering diagnostics company leveraging artificial intelligence and thermal imaging to revolutionize breast cancer screening. Its flagship Thermalytix platform offers a radiation-free, portable, and privacy-sensitive alternative to traditional mammography, with clinical validation supporting high accuracy across all ages and breast densities. With US FDA clearance for its SMILE-100 system, a growing global footprint, and strong backing from patents and clinical publications, Niramai is positioned to address critical gaps in early detection accessibility, particularly in low-resource and rural settings. The company represents a significant convergence of AI, medtech, and preventive healthcare.

Thermalytix: An AI-powered platform that analyzes high-resolution thermal images using machine learning algorithms to detect early-stage breast cancer based on abnormal heat patterns and vascular changes, without radiation or physical contact.

Niramai competes with traditional mammography and breast ultrasound, as well as emerging AI software that analyzes mammograms (e.g., Lunit, ScreenPoint Medical). Its primary differentiation is its radiation-free, contactless thermal imaging core, positioning it as a unique adjunctive tool and a potential primary screening solution in resource-constrained environments.